MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

被引:28
作者
Casaletto, Jessica B. [1 ]
Geddie, Melissa L. [1 ]
Abu-Yousif, Adnan O. [1 ]
Masson, Kristina [1 ]
Fulgham, Aaron [1 ]
Boudot, Antoine [1 ]
Maiwald, Tim [1 ]
Kearns, Jeffrey D. [1 ]
Kohli, Neeraj [1 ]
Su, Stephen [1 ]
Razlog, Maja [1 ]
Raue, Andreas [1 ]
Kalra, Ashish [1 ]
Hakansson, Maria [2 ]
Logan, Derek T. [2 ]
Welin, Martin [2 ]
Chattopadhyay, Shrikanta [1 ]
Harms, Brian D. [1 ]
Nielsen, Ulrik B. [1 ]
Schoeberl, Birgit [1 ]
Lugovskoy, Alexey A. [1 ]
MacBeath, Gavin [1 ]
机构
[1] Merrimack Pharmaceut Inc, Discovery Div, Cambridge, MA 02139 USA
[2] SAR Biostruct AB, SE-22381 Lund, Sweden
关键词
bispecific antibody; Met; HGF; EpCAM; cancer; HEPATOCYTE GROWTH-FACTOR; TIVANTINIB ARQ 197; RANDOMIZED PHASE-II; C-MET; ONCOGENE ADDICTION; CRYSTAL-STRUCTURE; INVASIVE GROWTH; PLUS ERLOTINIB; LUNG-CANCER; AMPLIFICATION;
D O I
10.1073/pnas.1819085116
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Activation of the Met receptor tyrosine kinase, either by its ligand, hepatocyte growth factor (HGF), or via ligand-independent mechanisms, such as MET amplification or receptor overexpression, has been implicated in driving tumor proliferation, metastasis, and resistance to therapy. Clinical development of Met-targeted antibodies has been challenging, however, as bivalent antibodies exhibit agonistic properties, whereas monovalent antibodies lack potency and the capacity to down-regulate Met. Through computational modeling, we found that the potency of a monovalent antibody targeting Met could be dramatically improved by introducing a second binding site that recognizes an unrelated, highly expressed antigen on the tumor cell surface. Guided by this prediction, we engineered MM-131, a bispecific antibody that is monovalent for both Met and epithelial cell adhesion molecule (EpCAM). MM-131 is a purely antagonistic antibody that blocks ligand-dependent and ligand-independent Met signaling by inhibiting HGF binding to Met and inducing receptor down-regulation. Together, these mechanisms lead to inhibition of proliferation in Met-driven cancer cells, inhibition of HGF-mediated cancer cell migration, and inhibition of tumor growth in HGF-dependent and -independent mouse xenograft models. Consistent with its design, MM-131 is more potent in EpCAM-high cells than in EpCAM-low cells, and its potency decreases when EpCAM levels are reduced by RNAi. Evaluation of Met, EpCAM, and HGF levels in human tumor samples reveals that EpCAM is expressed at high levels in a wide range of Met-positive tumor types, suggesting a broad opportunity for clinical development of MM-131.
引用
收藏
页码:7533 / 7542
页数:10
相关论文
共 74 条
[1]  
[Anonymous], 2015, J CLIN ONCOL S
[2]  
[Anonymous], 2011, Guide for the care and use of laboratory animals, DOI DOI 10.17226/12910
[3]  
[Anonymous], 2014, J CLIN ONCOL S
[4]   Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer [J].
Bahcall, Magda ;
Sim, Taebo ;
Paweletz, Cloud P. ;
Patel, Jyoti D. ;
Alden, Ryan S. ;
Kuang, Yanan ;
Sacher, Adrian G. ;
Kim, Nam Doo ;
Lydon, Christine A. ;
Awad, Mark M. ;
Jaklitsch, Michael T. ;
Sholl, Lynette M. ;
Jaenne, Pasi A. ;
Oxnard, Geoffrey R. .
CANCER DISCOVERY, 2016, 6 (12) :1334-1341
[5]   Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer [J].
Bardelli, Alberto ;
Corso, Simona ;
Bertotti, Andrea ;
Hobor, Sebastijan ;
Valtorta, Emanuele ;
Siravegna, Giulia ;
Sartore-Bianchi, Andrea ;
Scala, Elisa ;
Cassingena, Andrea ;
Zecchin, Davide ;
Apicella, Maria ;
Migliardi, Giorgia ;
Galimi, Francesco ;
Lauricella, Calogero ;
Zanon, Carlo ;
Perera, Timothy ;
Veronese, Silvio ;
Corti, Giorgio ;
Amatu, Alessio ;
Gambacorta, Marcello ;
Diaz, Luis A., Jr. ;
Sausen, Mark ;
Velculescu, Victor E. ;
Comoglio, Paolo ;
Trusolino, Livio ;
Di Nicolantonio, Federica ;
Giordano, Silvia ;
Siena, Salvatore .
CANCER DISCOVERY, 2013, 3 (06) :658-673
[6]   Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET plus NSCLC [J].
Bauer, Todd M. ;
Schuler, Martin ;
Berardi, Rossana ;
Lim, Wan-Teck ;
Van Geel, Robin ;
De Jonge, Maja ;
Azaro, Analia ;
Gottfried, Maya ;
Han, Ji-Youn ;
Lee, Dae Ho ;
Wollner, Mira ;
Hong, David ;
Voge, Arndt ;
Delmonte, Angelo ;
Krohn, Alexander ;
Zhang, Yong ;
Squires, Matthew ;
Giovannini, Monica ;
Akimov, Mikhail ;
Kim, Dong-Wan .
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) :S257-S258
[7]   MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib [J].
Bean, James ;
Brennan, Cameron ;
Shih, Jin-Yuan ;
Riely, Gregory ;
Viale, Agnes ;
Wang, Lu ;
Chitale, Dhananjay ;
Motoi, Noriko ;
Szoke, Janos ;
Broderick, Stephen ;
Balak, Marissa ;
Chang, Wen-Cheng ;
Yu, Chong-Jen ;
Gazdar, Adi ;
Pass, Harvey ;
Rusch, Valerie ;
Gerald, William ;
Huang, Shiu-Feng ;
Yang, Pan-Chyr ;
Miller, Vincent ;
Ladany, Marc ;
Yang, Chih-Hsin ;
Pao, William .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (52) :20932-20937
[8]   Met, metastasis, motility and more [J].
Birchmeier, C ;
Birchmeier, W ;
Gherardi, E ;
Vande Woude, GF .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) :915-925
[9]  
BOCCACCIO C, 1994, J BIOL CHEM, V269, P12846
[10]   A randomized, open-label, phase 2 study of emibetuzumab plus erlotinib (LY plus E) and emibetuzumab monotherapy (LY) in patients with acquired resistance to erlotinib and MET diagnostic positive (MET Dx plus ) metastatic NSCLC. [J].
Camidge, D. Ross ;
Moran, Teresa ;
Demedts, Inge ;
Grosch, Heidrun ;
Di Mercurio, Jean-Pierre ;
Mileham, Kathryn Finch ;
Molina, Julian R. ;
Vidal, Oscar Juan ;
Bepler, Gerold ;
Goldman, Jonathan Wade ;
Lewanski, Conrad ;
Park, Keunchil ;
Wallin, Johan ;
Wijayawardana, Sameera R. ;
Wang, Xuejing Aimee ;
Wacheck, Volker ;
Smit, Egbert F. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)